Indusatumab vedotin

• Description :

  Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162) . Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis[1].

• Product Name Alternative :

  MLN0264; TAK-264

• UNSPSC :

  12352203

• Target :

  Antibody-Drug Conjugates (ADCs) ; Apoptosis; Guanylate Cyclase

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Apoptosis; GPCR/G Protein

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Purity :

  96.37

• Solubility :

  10 mM in DMSO

• Smiles :

  [Indusatumabvedotin]

• References & Citations :

  [1]Schreiber AR, et al. Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Clin Cancer Drugs. 2018;5 (1) :42-49. |[2]Teng S W, et al. Using pharmacokinetic/efficacy modeling to identify the optimal schedule for MLN0264, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate, in a range of xenograft models[J]. Cancer Research, 2014, 74 (19_Supplement) : 4649-4649.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  -80°C, protect from light

• Scientific Category :

  ADC Related

• Clinical Information :

  Phase 2

• CAS Number :

  [1514889-12-3]